Frost Radar™: US Liquid Biopsy, 2022

Frost Radar™: US Liquid Biopsy, 2022

A Benchmarking System to Spark Companies to Action - Innovation that Fuels New Deal Flow and Growth Pipelines

RELEASE DATE
23-Aug-2022
REGION
North America
Research Code: PD7A-01-00-00-00
SKU: HC03576-GL-MR_26831
$4,950.00
In stock
SKU
HC03576-GL-MR_26831
$4,950.00

Pay by invoice

ENQUIRE NOW

Description

The oncology space is maturing rapidly. With the arrival of blood-based assays for cancer screening and the emphasis on early detection, the liquid biopsy segment is seeing increased consolidation and high-impact acquisitions, such as Illumina and GRAIL, Exact Sciences and Thrive Earlier Detection, and Roche Foundation Medicine and Lexent Bio. Comprehensive multi-cancer tests with companion diagnostic claims received approval in late 2020. Driven by multiple FDA liquid biopsy approvals in 2021, the ability to diagnose a tumor and monitor its progression and treatment response without performing a tissue biopsy is one of the most groundbreaking advancements in the In vitro diagnostics (IVD) market. In a field of more than 35 US industry participants, Frost & Sullivan independently plotted the top 9 Liquid Biopsy companies in this Frost Radar™ analysis: GRAIL, Exact Sciences Corp., Roche Foundation Medicine, Guardant Health, Natera, Inc., Helio Genomics (formerly Helio Health, Helio), Freenome, Quanterix, and Tempus, Inc., that are truly innovating and best positioned to deliver high value to customers in the future.

Author: Amartya Bose

RESEARCH: INFOGRAPHIC

This infographic presents a brief overview of the research, and highlights the key topics discussed in it.
Click image to view it in full size

Table of Contents

Strategic Imperative

Growth Environment

Frost Radar™: US Liquid Biopsy Market

Frost Radar™: Competitive Environment

Frost Radar™: Competitive Environment (continued)

GRAIL

Exact Sciences Corp

Roche Foundation Medicine

Guardant Health

Natera, Inc.

Helio Genomics

Quanterix Corp

Freenome

Tempus, Inc.

Strategic Insights

Significance of Being on the Frost Radar™

Frost Radar™ Empowers the CEO’s Growth Team

Frost Radar™ Empowers Investors

Frost Radar™ Empowers Customers

Frost Radar™ Empowers the Board of Directors

Frost Radar™: Benchmarking Future Growth Potential

Frost Radar™: Benchmarking Future Growth Potential

Legal Disclaimer

The oncology space is maturing rapidly. With the arrival of blood-based assays for cancer screening and the emphasis on early detection, the liquid biopsy segment is seeing increased consolidation and high-impact acquisitions, such as Illumina and GRAIL, Exact Sciences and Thrive Earlier Detection, and Roche Foundation Medicine and Lexent Bio. Comprehensive multi-cancer tests with companion diagnostic claims received approval in late 2020. Driven by multiple FDA liquid biopsy approvals in 2021, the ability to diagnose a tumor and monitor its progression and treatment response without performing a tissue biopsy is one of the most groundbreaking advancements in the In vitro diagnostics (IVD) market. In a field of more than 35 US industry participants, Frost & Sullivan independently plotted the top 9 Liquid Biopsy companies in this Frost Radar™ analysis: GRAIL, Exact Sciences Corp., Roche Foundation Medicine, Guardant Health, Natera, Inc., Helio Genomics (formerly Helio Health, Helio), Freenome, Quanterix, and Tempus, Inc., that are truly innovating and best positioned to deliver high value to customers in the future. Author: Amartya Bose
More Information
Author Amartya Bose
Industries Healthcare
No Index No
Is Prebook No
Keyword 1 Liquid Biopsy Market 2022
Keyword 2 US Liquid Biopsy Market
Keyword 3 In vitro diagnostics (IVD) market
Podcast No
WIP Number PD7A-01-00-00-00